75985-23-8 Usage
Uses
Used in Pharmaceutical Industry:
4-Pyrimidinemethanamine, 5-methyl(9CI) is used as a chemical intermediate for the preparation of pyridazinone derivatives that function as P2X7 receptor inhibitors. These inhibitors are being explored for their potential therapeutic effects in treating conditions such as rheumatoid arthritis, by modulating the immune response and reducing inflammation.
Used in Research and Development:
In addition to its pharmaceutical applications, 4-Pyrimidinemethanamine, 5-methyl(9CI) is also utilized in research and development settings. Scientists use 4-Pyrimidinemethanamine, 5-methyl- (9CI) to study the structure-activity relationships of P2X7 receptor inhibitors and to develop new drugs with improved efficacy and safety profiles. This research can contribute to the advancement of treatments for various inflammatory and immune-related disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 75985-23-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,9,8 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 75985-23:
(7*7)+(6*5)+(5*9)+(4*8)+(3*5)+(2*2)+(1*3)=178
178 % 10 = 8
So 75985-23-8 is a valid CAS Registry Number.
75985-23-8Relevant academic research and scientific papers
AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
, (2016/06/21)
Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS
-
Page/Page column 170, (2009/06/27)
Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
